Class 1, 2 and 3 integrons in clinical Pseudomonas aeruginosa isolated from Tanta University Hospitals, Egypt.

Pseudomonas aeruginosa has become a significant health threat, as it has developed resistance to multiple antimicrobial drugs. In this study, we aimed to identify class 1, 2 and 3 integrons in clinical P. aeruginosa isolates for the first time in Egypt, and detect their relationship with antibiotic resistance. A total of 192 clinical P. aeruginosa isolates were gathered from Tanta University Hospitals. One hundred and thirteen isolates (58.9%) were multidrug- resistant, and 38 isolates (19.8%) were resistant to all drugs tested. Class 1 integrons were detected in 87 isolates (45.3%), while class 2 and 3 integrons were not detected. This is the first report of a profile of integrons in P. aeruginosa from Egypt. The detection of only class 1 integrons in our isolates suggests that other genetic elements may be responsible for the distribution of antibiotic resistance in our setting. Aztreonam and colistin were the drugs of choice for the treatment of infections with P. aeruginosa.

In vitro activity of plazomicin against quinolone-resistant gram-negative bacteria isolated from catheter-associated urinary tract infections.

Quinolone resistance among uropathogens is an increasing concern. Plazomicin is a new aminoglycoside that shows promising results against resistant bacteria. However, no study has yet tested its effect specifically on quinolone-resistant organisms. This study aimed to evaluate the in vitro activity of plazomicin and comparator drugs against quinolone-resistant Gram-negative isolates of catheter-associated urinary tract infections (CAUTI). Plazomicin demonstrated high inhibiting activity against Enterobacteriaceae isolates (95.9% at MIC≤ 2 mg/L), with MIC50/90 was 1/2 mg/L. High MICs values were detected against non-Enterobacteriaceae isolates (MIC50/90, 4/32 mg/L). Plazomicin had susceptibility rate of 97.2% against Enterobacteriaceae isolates carrying aminoglycosides modifying enzymes (AME) genes, while other aminoglycosides, amikacin and gentamicin showed reduced activity (32.4% and 25.4%, respectively). In conclusion, plazomicin showed potent in vitro activity against quinolone-resistant Enterobacteriaceae causing CAUTI, regardless of the AME pattern.